MHRA scientists move a needle-free Strep A vaccine a step closer
- Researchers at the UK medicines regulator, with the GSK Vaccines Institute for Global Health, tested a Strep A vaccine given through the nose or under the tongue.
- The vaccine uses GMMA, tiny bubbles shed by bacteria, as both a carrier and an immune booster.
- In mice it triggered immune responses at mucosal surfaces and throughout the body.
- There is still no licensed Strep A vaccine, and this is pre-clinical work that must be confirmed in humans.
Scientists at the Medicines and Healthcare products Regulatory Agency (MHRA), working with the GSK Vaccines Institute for Global Health, have published research that brings a vaccine against group A streptococcus (Strep A) a step closer. The paper, published in October 2026 in Human Vaccines & Immunotherapeutics, also suggests the vaccine could be given without a needle.
A common and sometimes deadly bacterium
Strep A causes sore throats and skin infections, but serious complications can lead to long-term disability or death. The MHRA cites estimates of more than 600 million Strep A infections worldwide each year and over 500,000 deaths from related complications, mostly in low- and middle-income countries. There is currently no licensed vaccine.
Also read: Jonas Salk: "There is no patent. Could you patent the sun?"
How the vaccine works
The experimental vaccine uses Generalised Modules for Membrane Antigens (GMMA), tiny bubbles naturally shed from bacteria, both to carry the Strep A carbohydrate antigen and to boost the immune response. Given through the nose or under the tongue, it generated strong immune responses both at mucosal surfaces, where infection starts, and throughout the body.
Dr Fatme Mawas, head of conjugate vaccines at the MHRA, said the approach could support a new generation of affordable, needle-free vaccines and, by preventing infections, help reduce antibiotic use and antimicrobial resistance.
Important limits
The study was conducted in mice. Results in animal models often do not translate directly to people, and safety, dosing and effectiveness will need to be tested in clinical trials before any Strep A vaccine can be licensed.
Source: MHRA (GOV.UK)
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
Is there a vaccine for Strep A?
No. There is currently no licensed vaccine against group A streptococcus (Strep A), although several candidates are in research.
What did the MHRA Strep A study find?
The MHRA study found that a GMMA-based Strep A vaccine given through the nose or under the tongue produced strong mucosal and whole-body immune responses in mice.
What is GMMA in vaccines?
GMMA (Generalised Modules for Membrane Antigens) are tiny bubbles naturally shed by bacteria, used in vaccines both to carry antigens and to boost the immune response.
Was the needle-free Strep A vaccine tested in humans?
No. The MHRA needle-free Strep A vaccine research was pre-clinical and conducted in mice, so human trials are still needed.
How many people does Strep A affect worldwide?
The MHRA cites estimates of more than 600 million Strep A infections worldwide each year, with complications responsible for over 500,000 deaths.


